Breakpoints19 Feb 2021

#34 – The New Scoop on Poop: Updates in the Management of C. difficile infections

Dr. Kevin Garey (@GareyKgarey), Dr. Kelly Reveles (@KellyReveles), Dr. Mandelin Cooper, and host Dr. Rachel Britt (@RachelBPharmD) discuss proposed updates of the IDSA-SHEA C. difficile guidelines, including: fidaxomicin over oral vancomycin as first-line therapy, the roles and logistical hurdles of fecal microbiota transplant, bezlotoxumab, and the pros and cons of prophylaxis.

Timestamps

1:16 - Panel introductions 3:19 - Fidaxomicin vs PO vancomycin for first occurrence 7:21 - Fidaxomicin cost effectiveness 11:26 - Factors to consider for health systems when considering switch to fidaxomicin 14:23 - Fidaxomicin vs PO vancomycin for recurrences 17:52 - Role of pulsed and tapered PO vancomycin 19:57 - Role of fecal microbiota transplant (FMT) 22:24 - Challenges of FMT and where pharmacy fits in 27:27 - Bezlotoxumab 31:54 - Feasibility issues with bezlotoxumab and strategies to address them 35:25 - CDI prophylaxis 40:28 - Stewardship's role in reducing C. difficile infections

References

Fidaxomicin Cost-effectiveness

Reveles KR, et al. Pharmacotherapy. 2017;37(12):1489-97.
Watt M, et al. Infection. 2016;44(5):599-606.
Cornely OA, et al. J Antimicrob Chemother. 2018;73(9):2529-39.
Rubio-Terres C, et al. Eur J Clin Microbiol Infect Dis. 2019;38(6):1105-11.

Bezlotoxumab

Wilcox MH, et al. N Engl J Med. 2017;376:305-17.
Oksi J, et al. Eur J Clin Microbiol Infect Dis. 2019;38(10):1947-52.
Hengel RL, et al. Open Forum Infect Dis. 2020;7(4):ofaa097.

Bezlotoxumab Cost-effectiveness

Salavert M, et al. Adv Ther. 2018;35(11):1920-34.
Prabhu VS, et al. Clin Infect Dis. 2018;66(3):355-62.

Primary prophylaxis

Pereiras MA, et al. Biol Blood Marrow Transplant. 2017; 23:S395.
Ganetsky A, et al. Clin Infect Dis. 2019;68(12):2003-2009.
Mullane KM, et al. Clin Infect Dis. 2019; 68(2):196–203.

Secondary prophylaxis

Carignan A, et al. Am J Gastroenterol. 2016;111:1834-1840.
Van Hise NW, et al. Clin Infect Dis. 2016;63:651-653.
Splinter et al. Ann Pharmacother. 2018;52:113-119.
Knight EM, et al. J Pharm Pract. 2019;:897190019825994.
Morrisette T, et al. Biol Blood Marrow Transplant. 2019;25(10):2091-2097.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(142)

#142 – Does oseltamivir harm critically ill patients? The REMAP-CAP results

Does oseltamivir harm critically ill patients with influenza? In this Breakpoints and Communicable collaboration, Erin McCreary and Josh Davis are joined by Steve Webb and Steve Tong to discuss the RE...

20 Sep 1h 3min

#141 – Prostatitis: Hard to Reach, Harder to Treat

Dr. Prathit Kulkarni, lead author of a recent state-of-the-art review on acute and chronic bacterial prostatitis, joins host Dr. Erin McCreary to discuss this complex disease state. They walk through ...

11 Sep 58min

#140 – Beta-lactamase inhibitors: “Scientifically elegant, just complex"

Gram-negative resistance is beautifully intricate, scientifically elegant, and very complex. Nothing is more exciting than the recently approved and bursting pipeline of beta-lactamase inhibitors. Lis...

21 Aug 1h 16min

#139 – The ART of HIV Care: Evidence, Pearls and Practice

Join Dr. Whitney Buckel and leading HIV experts Dr. William Short and Dr. Ryan Tomlin for an engaging discussion on the current and future state of HIV care. As treatment and prevention options conti...

31 Jul 1h 9min

#138 – You CAN Go Home Again: A review of OPAT and CoPAT from the MAD-ID/SIDP Annual Meeting

In this must-listen episode, Dr. Ryan Moenster is joined by Dr. Monica Mahoney and Dr. Mark Gilchrist to dive deep into the evolving landscape of outpatient parenteral antimicrobial therapy (OPAT) and...

3 Jul 1h 14min

#137 – Hot Topics: What You May Have Missed in Infectious Diseases 2025-2026 (LIVE from MAD-ID)

In this must-listen episode, Dr. Ryan Moenster and Dr. Megan Klatt dive deep into the latest infectious diseases trials, guidelines, and novel therapeutics. Staying current in the field is a challenge...

19 Jun 1h 8min

#136 – GAS, Streptococcus pyogenes: Call It What You Want, It’s Got a Big Reputation

Group A Streptococcal infections remain a global challenge, spanning common conditions like pharyngitis to severe invasive disease. Dr. Shiranee Sriskandan, Dr. Josh Osowicki, and Dr. Tom Parks join h...

5 Jun 1h 25min

#135 – Stewie Struggles: Small Hospital Edition

Small hospitals bring unique stewardship challenges, but also unique opportunities. Dr. Tina Khadem and Dr. Ashley Cubillos join host Dr. Whitney Buckel to discuss the realities of antimicrobial stewa...

22 Mai 1h 2min